The expression of mammaglobin mRNA in peripheral blood of metastatic breast cancer patients as an adjunct to serum tumor markers

Cancer Lett. 2003 Feb 28;191(1):93-9. doi: 10.1016/s0304-3835(02)00545-1.

Abstract

We conducted a study to compare the expression of human mammaglobin (hMAM) mRNA in breast cancer patients' peripheral blood with serum carcinoembryonic antigen (CEA) and CA 15.3. A total of 33 metastatic breast cancer patients were enrolled. The blood samples were used to test the expression of hMAM mRNA by reverse transcriptase polymerase chain reaction (RT-PCR) and CEA, CA 15.3 by radioimmunoassay. The serum CEA and CA 15.3 levels were elevated in 17 (51%) and 23 (69%) of the patients, respectively. When combined CEA with CA 15.3, the sensitivity rate raised to 78%. hMAM mRNA was detected in 18 (54%) of the 33 patients. When combined hMAM mRNA with CEA or CA 15.3, the sensitivity rate were 81% and 90%, respectively (P=0.045). In conclusion, the hMAM mRNA RT-PCR can be an adjunct in detecting metastatic breast cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / blood*
  • Breast Neoplasms / blood*
  • Breast Neoplasms / diagnosis
  • Breast Neoplasms / pathology
  • Carcinoembryonic Antigen / analysis
  • Female
  • Humans
  • Mammaglobin A
  • Middle Aged
  • Mucin-1 / blood
  • Neoplasm Metastasis
  • Neoplasm Proteins / genetics*
  • Predictive Value of Tests
  • RNA, Messenger / blood*
  • RNA, Neoplasm / blood*
  • Radioimmunoassay
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sensitivity and Specificity
  • Tumor Cells, Cultured / chemistry
  • Uteroglobin / genetics*

Substances

  • Biomarkers, Tumor
  • Carcinoembryonic Antigen
  • Mammaglobin A
  • Mucin-1
  • Neoplasm Proteins
  • RNA, Messenger
  • RNA, Neoplasm
  • SCGB2A2 protein, human
  • Uteroglobin